Skip to Main Content
Professional Photo

Robin L. Teskin


Robin Teskin is an experienced patent attorney and advises a wide range of clients, including established and start-up biotechnology, chemical and pharmaceutical companies and prominent research universities.

Professional Biography

Robin Teskin focuses her practice on intellectual property law, with an emphasis on the biotechnology, pharmaceutical and chemical industries. Robin provides intellectual property advice to pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, hospitals and universities throughout the world. Her practice includes patent prosecution, post-grant proceedings, licensing and transactional work with a focus on novel therapeutic treatments, biotechnology, polymers, genetics, diagnostics, biomarkers, nutraceuticals, probiotics, drug formulations and medical devices.

Ms. Teskin's more than 30 years of patent law experience involves all aspects of patent counseling and patent prosecution, including freedom-to-operate, due diligence, non-infringement, inventorship, invalidity, and Hatch-Waxman legal issues. Additionally, Ms. Teskin has experience in post-grant patent office proceedings including reissues, inter partes reviews (IPRs), post-grant reviews (PGRs), ex parte reexaminations and interferences.

Ms. Teskin's intellectual property experience spans a wide range of cutting-edge technologies including therapeutic antibodies, small molecules, polymer chemistry, vaccines, embryonic stem cells, transgenic animals, nuclear transfer, CRISPR, CAR-T cell and other cell therapies, transplantation, nucleic and protein detection methods, microfluidics, medical devices and automated diagnostic assays. She has substantial expertise in therapeutic antibodies, having managed the prosecution of a global patent portfolio covering the first therapeutic antibody approved by the FDA for use in treating human cancer. Ms. Teskin also has significant experience in overseeing patent portfolios relating to drugs which target checkpoint inhibitors. Further, Ms. Teskin has much experience counseling clients pursuing intellectual property relating to stem cell and nuclear transfer technologies, having managed the global portfolio of a major research university which procured the first patents directed to the nuclear transfer production of cloned animals and embryos, and further through her having managed the global patent portfolio of an emerging company pursuing intellectual property covering the manufacture of human cells derived from human embryonic stem cells for use in human cell therapies (e.g., the treatment of macular degeneration).

Prior to her admission to the bar, Ms. Teskin served as an assistant and primary patent examiner at the U.S. Patent and Trademark Office (USPTO), where she was among the first examiners selected to be part of the then-newly formed USPTO Biotechnology Group. While an examiner, she issued about 500 patents dealing with complex biotechnology research and was awarded a Bronze Medal for distinguished federal service.

  • Manage a global patent portfolio for a European company developing novel CAR-T cell therapies for use in cancer and infectious diseases.

  • Prosecuted and successfully defended a patent covering TCR-deficient human T cells for use in human therapy against two third-party challenges.

  • Manage the global patent portfolio for a biotechnology company pursuing therapeutic antibodies for use in neurology indications including migraine, yeast fermentation methods, and novel platform technology for producing antibody secreting B cells and high affinity therapeutic antibodies.

  • Manage the global patent portfolio for a biotechnology company pursuing therapeutic antibodies and fusion proteins targeting a novel checkpoint inhibitor.

  • Oversee a global patent portfolio for an international company pursuing water purification, pulp processing and oil recovery methods.

  • Oversee a global patent portfolio for a company's novel biomarkers and drugs for use in pancreatic and colon cancer treatment.

  • Oversee the prosecution of a global patent portfolio directed to antibodies targeting NK cell receptors and their usage in oncology and infectious disease indications.

  • Oversee the prosecution of patent portfolios directed to FGF-21 and relaxin variants for use in human therapy.

  • Conduct numerous due diligence investigations for a prominent international company involved in nucleic acid and protein detection methods for use in diagnosis of cancer and other human disease conditions.

  • Managed patent prosecution worldwide on behalf of prominent biotech company involved in therapeutic antibody development including intellectual property relating to a chimeric antibody approved for the treatment of non-Hodgkin's lymphoma as well as a radiolabeled antibody approved for the treatment of cancer.

  • Represented a prominent research university in an interference at the patent and trademark office and the Federal Circuit relating to a therapeutic antibody approved for the treatment of autoimmune disorders.

  • Drafted and prosecuted to issuance first patents directed to cloning and nuclear transfer on behalf of a major research university and its exclusive licensee.

  • Represented a major research university in an interference matter involving real-time polymerase chain reaction techniques. Obtained a non-interference in fact ruling favorable to the client.

  • Provide IP counseling and supporting opinions for numerous biotechnology and pharmaceutical clients, especially Hatch-Waxman litigation related matters.

  • Conduct numerous due diligence investigations, including one involving a major patent acquisition by a pharmaceutical company that resulted in the client acquiring a large patent estate (more than 800 patents) and significantly streamlining the portfolio to minimize patent costs while maintaining key strategic patents.

  • Drafted and prosecuted to declaration of interference (four-party) a pioneering patent relating to a cervical cancer vaccine on behalf of a prominent university that was licensed by a prominent biotechnology company.

  • Prepared and filed numerous patent term extensions for biologics and pharmaceuticals.

  • Co-represented a company at the forefront of stem cell technology and nuclear transfer cloning in a three-way interference involving pioneering nuclear transfer cloning technology.

  • Manage and prosecute the IP portfolio for a company at the forefront of taste and olfactory receptor technology recently acquired by a prominent international company involved in flavorants.

  • Prosecuted patents in relation to animals, such as avian and porcine vaccines.

  • Provided freedom to operate and invalidity opinions regarding competitor patents related to animal vaccines.

  • Prepared applications relating to "caninized" and "felinized" antibodies for use in treatment of canine/feline oncology.

  • Prepared and prosecuted patents relating to veterinary diagnostics.

  • Named Virginia Business magazine's "Legal Elite" in Intellectual Property Law
  • Bronze Medal, USPTO
  • Examiner on U.S. Patent No. 5,000,000
  • American Bar Association
  • District of Columbia Bar Association
  • Association of University Technology Managers
  • Intellectual Property Owners Association
  • Presented at numerous Eastern Region AUTM meetings (2010 – 2016)
  • Panel member at different therapeutic antibody conferences (2012 – 2015)


  • George Washington University Law School, J.D., with honors, 1994
  • Stevens Institute of Technology, MChE, 1983, cum laude
  • Montclair State University, Biology and Chemistry, mathematics minor, 1980


  • District of Columbia, 2000
  • Virginia, 1995
  • U.S. Patent and Trademark Office, 1991

Email Disclaimer

NOTICE: The mailing of this email is not intended to create, and receipt of it does not constitute an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Cancel Accept